Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Oncogenesis driven by the Ras/Raf pathway requires the SUMO E2 ligase Ubc9.

Proceedings of the National Academy of Sciences of the United States of America - 7 Apr 2015

Yu Bing, Swatkoski Stephen, Holly Alesia, Lee Liam C, Giroux Valentin, Lee Chih-Shia, Hsu Dennis, Smith Jordan L, Yuen Garmen, Yue Junqiu, Ann David K, Simpson R Mark, Creighton Chad J, Figg William D, Gucek Marjan, Luo Ji

Abstract excerpt

The small GTPase KRAS is frequently mutated in human cancer and currently there are no targeted therapies for KRAS mutant tumors. Here, we show that the small ubiquitin-like modifier (SUMO) pathway is required for KRAS-driven transformation. RNAi depletion of the SUMO E2 ligase Ubc9 suppresses 3D growth of KRAS mutant colorectal cancer cells in vitro and attenuates tumor growth in vivo. In KRAS mutant cells, a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Caco-2 Cells
Share to HCT116 Cells

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mice, Inbred NOD

Share to Mice, SCID

Share to Neoplasm Transplantation

Share to raf Kinases

Share to Ubiquitin-Conjugating Enzyme UBC9

Share to Ubiquitin-Conjugating Enzymes

Source

Open in PubMed Open full text

Identifiers

PMID: 25805818
DOI: 10.1073/pnas.1415569112
PMCID: PMC4394293

Genes

KRAS
CHD1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Oncogenesis driven by the Ras/Raf pathway requires the SUMO E2 ligase Ubc9.PMID 25805818Read ↗

RASH3D19 mediates RAS activation through a positive feedback loop in KRAS-mutant cancer.Semantic proximity Read ↗

Genetic identification of the RAS proteostatic machinery and its failure to regulate oncogenic variantsSemantic proximity Read ↗

Protein-RNA interaction dynamics reveal key regulators of oncogenic KRAS-driven cancers.Semantic proximity Read ↗

Defining the KRAS- and ERK-dependent transcriptome in KRAS-mutant cancers.Semantic proximity Read ↗

Oncogenic mutations of KRAS modulate its turnover by the CUL3/LZTR1 E3 ligase complex.Semantic proximity Read ↗

Oncogenic KRAS is dependent upon an EFR3A-PI4KA signaling axis for potent tumorigenic activity.Semantic proximity Read ↗

PDP1 promotes KRAS mutant colorectal cancer progression by serving as a scaffold for BRAF and MEK1.Semantic proximity Read ↗

KRAS Engages AGO2 to Enhance Cellular Transformation.Semantic proximity Read ↗

Interplay Between KRAS and LZTR1 Protein Turnover, Controlled by CUL3/LZTR1 E3 Ubiquitin Ligase, is Disrupted by KRAS MutationsSemantic proximity Read ↗

Dual inhibition of SUMOylation and MEK conquers MYC-expressing KRAS-mutant cancers by accumulating DNA damage.Semantic proximity Read ↗

Targeting Smurf1 to block PDK1-Akt signaling in KRAS-mutated colorectal cancer.Semantic proximity Read ↗

SHANK3 depletion leads to ERK signalling overdose and cell death in KRAS-mutant cancers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.